Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Transcriptional mediators of treatment resistance in lethal prostate cancer

Open access
He, Meng Xiao, Cuoco, Michael S., Crowdis, Jett, Bosma-Moody, Alice, Zhang, Zhenwei, Bi, Kevin, Kanodia, Abhay, Su, Mei-Ju, Ku, Sheng-Yu, Garcia, Maria Mica, Sweet, Amalia R., Rodman, Christopher, DelloStritto, Laura, Silver, Rebecca, Steinharter, John, Shah, Parin, Izar, Benjamin, Walk, Nathan C., Burke, Kelly P., Bakouny, Ziad, Tewari, Alok K., Liu, David, Camp, Sabrina Y., Vokes, Natalie I., Salari, Keyan, Park, Jihye, Vigneau, Sébastien, Fong, Lawrence, Russo, Joshua W., Yuan, Xin, Balk, Steven P., Beltran, Himisha, Rozenblatt-Rosen, Orit, Regev, Aviv, Rotem, Asaf, Taplin, Mary-Ellen, Van Allen, Eliezer M. · 2021 · Nature Medicine

Abstract

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors 1 . Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites. Irrespective of treatment exposure, adenocarcinoma cells pervasively coexpressed multiple androgen receptor isoforms, including truncated isoforms hypothesized to mediate resistance to androgen-targeting therapies 2,3 . Resistance to enzalutamide was associated with cancer cell–intrinsic epithelial–mesenchymal transition and transforming growth factor-β signaling. Small cell carcinoma cells exhibited divergent expression programs driven by transcriptional regulators promoting lineage plasticity and HOXB5, HOXB6 and NR1D2 (refs. 4–6 ). Additionally, a subset of patients had high expression of dysfunction markers on cytotoxic CD8 + T cells undergoing clonal expansion following enzalutamide treatment. Collectively, the transcriptional characterization of cancer and immune cells from human metastatic castration-resistant prostate cancer provides a basis for the development of therapeutic approaches complementing androgen signaling inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01244-6

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 184

Metadata

Authors
He, M. X., Cuoco, M. S., Crowdis, J., Bosma-Moody, A., Zhang, Z., Bi, K., Kanodia, A., Su, M.-J., Ku, S.-Y., Garcia, M. M., Sweet, A. R., Rodman, C., DelloStritto, L., Silver, R., Steinharter, J., Shah, P., Izar, B., Walk, N. C., Burke, K. P., Bakouny, Z., Tewari, A. K., Liu, D., Camp, S. Y., Vokes, N. I., Salari, K., Park, J., Vigneau, S., Fong, L., Russo, J. W., Yuan, X., Balk, S. P., Beltran, H., Rozenblatt-Rosen, O., Regev, A., Rotem, A., Taplin, M.-E., & Van Allen, E. M.
Venue
Nature Medicine
Published
2021-03
Volume
27
Issue
3
Pages
426-433
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3135324733
Cited by
184
References
22
FWCI
18.86
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptional mediators of treatment resistance in lethal prostate cancer. https://app.cochat.ai/papers/10.1038/s41591-021-01244-6
The paper
He, M. X., Cuoco, M. S., Crowdis, J., Bosma-Moody, A., Zhang, Z., Bi, K., Kanodia, A., Su, M.-J., Ku, S.-Y., Garcia, M. M., Sweet, A. R., Rodman, C., DelloStritto, L., Silver, R., Steinharter, J., Shah, P., Izar, B., Walk, N. C., Burke, K. P., . . . Van Allen, E. M. (2021). Transcriptional mediators of treatment resistance in lethal prostate cancer. Nature Medicine. https://doi.org/10.1038/s41591-021-01244-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.